---
schema_version: "secwatch.filing_event.v1"
accession: "0001023024-23-000041"
form_type: "8-K"
ticker: "ANIP"
cik: "0001023024"
company_name: "ANI PHARMACEUTICALS INC"
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T08:30:25.477306+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# ANI Pharma Q3 revenue $131.8M (+57% YoY); raises FY2023 guidance

## Summary
- Record Q3 net revenue $131.8M, up 57.3% YoY; GAAP net income $9.5M ($0.45 diluted EPS).
- Adjusted non-GAAP EBITDA $36.5M (+98% YoY); adj. diluted EPS $1.27 vs $0.58 YoY.
- Cortrophin Gel net sales $29.7M (+136% YoY); full-year Cortrophin guidance raised to $100M-$107M.
- FY2023 revenue guidance raised to $468M-$478M (prev. $425M-$445M); adj. EPS guided $4.29-$4.57.
- Generics/Established Brands revenue $102.1M (+43.4% YoY); 5 new products launched in Q3.

## SEC filing metadata
- accession: 0001023024-23-000041
- form_type: 8-K
- ticker: ANIP
- cik: 0001023024
- company_name: ANI PHARMACEUTICALS INC
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1023024/000102302423000041/0001023024-23-000041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1023024/000102302423000041/ani-20231108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001023024-23-000041
- JSON: https://secwatch.observer/filing/0001023024-23-000041.json
- Plain text: https://secwatch.observer/filing/0001023024-23-000041.txt

## Key facts
- Earnings Releases
  ANI PHARMACEUTICALS INC reported the quarter ended September 30, 2023 results: revenue $131.8 million, net income $9.5 million, EPS $0.45. Guidance raised.
  - Period: the quarter ended September 30, 2023
  - Revenue: $131.8 million
  - Net income: $9.5 million
  - EPS: $0.45
  - Guidance: raised
  - Result: reported results
  source text: Pharmaceuticals Reports Record Third Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance Third Quarter 2023 Financial Results -- Record quarterly net revenues of $131.8 million, representing year-over-year growth of 57.3%; net income available to common shareholders of $9.5 million and diluted GAAP income per share of $0.45 -- -- Record quarterly
  evidence_url: https://www.sec.gov/Archives/edgar/data/1023024/000102302423000041/0001023024-23-000041-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.